- Home
- TSVT vs VNDA Comparison
TSVT vs VNDA Comparison
Compare TSVT & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSVT
- VNDA
- Stock Information
- Founded
- TSVT 2021
- VNDA 2002
- Country
- TSVT United States
- VNDA United States
- Employees
- TSVT N/A
- VNDA N/A
- Industry
- TSVT Biotechnology: Pharmaceutical Preparations
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- TSVT Health Care
- VNDA Health Care
- Exchange
- TSVT Nasdaq
- VNDA Nasdaq
- Market Cap
- TSVT 258.9M
- VNDA 237.9M
- IPO Year
- TSVT N/A
- VNDA 2006
- Fundamental
- Price
- TSVT $4.98
- VNDA $4.33
- Analyst Decision
- TSVT Buy
- VNDA Strong Buy
- Analyst Count
- TSVT 4
- VNDA 2
- Target Price
- TSVT $6.50
- VNDA $16.50
- AVG Volume (30 Days)
- TSVT 1.1M
- VNDA 754.6K
- Earning Date
- TSVT 05-07-2025
- VNDA 05-07-2025
- Dividend Yield
- TSVT N/A
- VNDA N/A
- EPS Growth
- TSVT N/A
- VNDA N/A
- EPS
- TSVT N/A
- VNDA N/A
- Revenue
- TSVT $37,862,000.00
- VNDA $198,772,000.00
- Revenue This Year
- TSVT $84.48
- VNDA $14.36
- Revenue Next Year
- TSVT $9.69
- VNDA $44.53
- P/E Ratio
- TSVT N/A
- VNDA N/A
- Revenue Growth
- TSVT N/A
- VNDA 3.18
- 52 Week Low
- TSVT $2.29
- VNDA $3.85
- 52 Week High
- TSVT $5.30
- VNDA $6.75
- Technical
- Relative Strength Index (RSI)
- TSVT 76.79
- VNDA 43.42
- Support Level
- TSVT $4.88
- VNDA $4.27
- Resistance Level
- TSVT $4.99
- VNDA $4.46
- Average True Range (ATR)
- TSVT 0.03
- VNDA 0.22
- MACD
- TSVT -0.08
- VNDA 0.01
- Stochastic Oscillator
- TSVT 90.91
- VNDA 54.55
About TSVT 2seventy bio Inc.
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.